Google
CHRS Stock Price & Analysis — Coherus Biosciences Inc (Healthcare >> Biotechnology)
CHRS FAQ
What is CHRS's ROE?
Coherus Biosciences Inc reports a Return on Equity (ROE) of -192.90%.
What is CHRS's dividend yield?
Coherus Biosciences Inc offers a dividend yield of 0.00%.
What is CHRS's Quality Score?
Our AI rates CHRS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CHRS?
Our AI Timing Score for CHRS is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CHRS belong to?
Coherus Biosciences Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
CHRS AI Analysis Summary
Our AI summary for CHRS: Coherus Biosciences Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -192.90%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.48
Price
0.04
(2.78%)
Day Change
|
|
|---|
CHRS, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.48 |
| PBV / Sector |
2.83 / 44,022.72
|
| Earning Per Share | -1.01 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
0.89 M
GREAT
|
| Average 1W Daily Value |
0.74 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-05 07:59:59 |
| Symbol | CHRS |
| Name | COHERUS BIOSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 154.25 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 222.12 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065
Phone: 650 649 3530
Website: https://www.coherus.com
Employees: 145
Sector: Healthcare >> Biotechnology
Description: Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap